Egide (ALGID) investor relations material

Executive summary

• Consolidated revenue for H1 2026 was €15.2m, down 2.4% year-over-year on a reported basis but up 0.7% at constant exchange rates.

• Egide SA posted strong growth, up 28% to €10.03m, offsetting declines in US operations.

• Egide USA revenue fell 33% to €3.80m due to customer program delays, with recovery expected in H2 2026.

• Santier's revenue dropped 34% to €1.38m following the cessation of production in April 2026.

Financial highlights

• Thermal Imaging revenue grew 23% to €8.38m, now representing 55% of group revenue.

• Power segment revenue declined 64% to €1.08m due to portfolio refocus.

• Microwave/RF and Optronics segments grew 42% and 15% respectively.

• Revenue in North America dropped 33% to €4.53m, while Asia & ROW grew 38% and Europe 9%.

Outlook and guidance

• Egide SA starts H2 2026 with a robust backlog and strong demand in strategic markets.

• Group expects weaker H2 2026 due to a high comparison base and seasonal effects, but positive year-on-year growth for Egide SA.

• North American recovery depends on ramp-up at Cambridge and customer program schedules.

• Transfer of Santier activities to Cambridge is underway, with gradual revenue contribution expected by 2027.